Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Herstal – page 51

1 407 clinical trials in Herstal, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Herstal at a glance
1 407
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 407 trials in Herstal

Open in trial search

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Crohn's disease

Not yet recruiting

Evaluation of Upadacitinib for Reducing Ileal Strictures in Patients with Crohn’s Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:UZ Leuven

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Celea Therapeutics Inc.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Propranolol Hydrochloride
  • Sponsor:Radboud universitair medisch centrum Stichting

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Posaconazole
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Partial seizures

Not yet recruiting

Safety and tolerability of OV329 as add‑on therapy in adults with drug‑resistant focal epilepsy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:OV329 hydrochloride
  • Sponsor:Ovid Therapeutics Inc.

Study of dupilumab added to standard care in adults hospitalized for COPD exacerbation to reduce readmissions, emergency visits, and death

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Herstal

What the registry says about research in the country

01 Immune System Diseases

Clinical research in Herstal is focused on immune system diseases, with all currently listed studies centered on atopic dermatitis. These trials are examining whether a new treatment approach can better control symptoms and improve everyday skin health for people living with moderate-to-severe disease.

  • Testing a new therapy for better control of atopic dermatitis
  • Comparing treatment effectiveness against placebo
  • Assessing improvements in skin signs and symptom severity

The research program in this Belgian city is aimed at understanding how well treatment options work for patients who need stronger support than standard care alone.

02 Atopic Dermatitis

The main disease under study is atopic dermatitis, a chronic inflammatory skin condition that can cause itching, redness, and discomfort. Current trials are looking at whether a targeted therapy can offer meaningful relief, either on its own or alongside common skin treatments.

  • Evaluating a new option for moderate-to-severe atopic dermatitis
  • Studying treatment used with topical corticosteroids and topical calcineurin inhibitors
  • Measuring changes in disease control and visible skin improvement
  • Supportive research for patients seeking better symptom management

These studies are designed to help clarify whether newer approaches can improve outcomes for people whose skin disease remains difficult to manage.

03 Topical Combination Treatment Research

Another important area of research is the use of topical corticosteroids and topical calcineurin inhibitors alongside investigational therapy. This work is focused on evaluating how combination treatment may improve relief and disease control compared with standard topical care alone.

  • Studying combination care for moderate-to-severe atopic dermatitis
  • Assessing whether added therapy improves overall response
  • Looking at clinical signs and severity over time

The trials in Belgium reflect a practical clinical question: whether pairing new and established treatments can lead to better outcomes for patients.

04 Therapeutic Innovation in Skin Inflammation

The local trial landscape is small but concentrated, with all active studies exploring a single inflammatory skin condition. This makes Herstal a focused site for research on newer therapies aimed at reducing the burden of persistent eczema symptoms.

  • Exploring a new treatment for inflammatory skin disease
  • Comparing benefit against standard control approaches
  • Helping define better options for routine patient care

Overall, the studies are centered on improving treatment effectiveness and expanding options for people living with difficult-to-treat skin inflammation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.